The vestibular nerve is the predilection site for schwannomas. Few transcriptomic studies have been performed on solely sporadic vestibular schwannomas (VSs). OBJECTIVE: To detect genes with altered expression levels in sporadic VSs. METHODS: We studied 25 VSs and 3 tibial nerves (controls) with the ABI 1700 microarray platform. Significance analysis of microarrays was performed to explore differential gene expression. Selected genes were validated with quantitative reverse transcriptase polymerase chain reaction. A tissue microarray was constructed for immunohistochemistry. Neurofibromatosis type II cDNA was sequenced for mutations. RESULTS: The VSs formed 2 clusters based on the total expression of 23 055 genes. Tumor size, previous Gamma Knife surgery, neurofibromatosis type II mutations, and cystic tumors were distributed equally in both. Significance analysis of microarrays detected 1650 differentially expressed genes. On the top 500 list, several cancer-related genes with an unrecognized role in VSs were down-regulated: CAV1, TGFB3, VCAM1, GLI1, GLI2, PRKAR2B, EPHA4, and FZD1. Immunohistochemistry showed no CAV1 expression in the VSs. The ERK pathway was the central core in the network linking the differentially expressed genes. The previously reported VS candidate genes SPARC, PLAT, and FGF1 were up-regulated. Nineteen of 25 VSs had NF2 mutations. CONCLUSION: Using microarray technology, we identified novel genes and pathways with a putative role in VSs, confirmed previous candidate genes, and found cancerrelated genes with no reported role in VSs. Among these, down-regulation of CAV1 at both the mRNA and protein levels is of particular interest because this tumor suppressor normally is expressed in Schwann cells. 1 The vast majority of VSs are unilateral and sporadic and not related to the autosomal dominant syndrome of neurofibromatosis type II (NF2) in which bilateral VSs are a hallmark of the disease. In adults, magnetic resonance imaging has shown that the prevalence is 0.2%, 2 and in Denmark the incidence in 2001 was 19.3/ million.
intracanalicular tumor. Little is known about possible molecular mechanisms behind these differences.
So far, the most important contribution to our understanding of VS biology has been the identification of the NF2 gene in 1993. 4 The gene encodes a 587-amino-acid protein named neurofibromin 2 (also known as merlin/schwannomin). Sainz et al, 5 who studied 30 VSs and detected NF2 mutations in 18 cases, found that the corresponding protein was absent in all cases and concluded that loss of neurofibromin 2 was an important step in schwannoma pathogenesis.
Nevertheless, because the NF2 gene is intact in a significant proportion of cases, 5 it is likely that other genes contribute to VS formation, by either separate unrecognized pathways or interfering with that of NF2. Detection of such pathways and candidate genes has been greatly facilitated by the introduction of mRNA microarray analysis. Until now, only few such studies on purely sporadic VSs have been performed. 6 Studies including mixtures of sporadic, peripheral, and NF2-associated VSs show altered expression levels have been found for the SPARC, RBM5, AKT1, PLAT, PLAU, FGF1, and TP53 genes. [7] [8] [9] The series are small, and samples from various sources of nerve tissue were used as controls in these studies.
We therefore conducted a microarray-based study on 25 sporadic VSs in which the main purposes were (1) to determine the general gene expression signature of the tumors and (2) to identify potential candidate genes and pathways involved in VS biology.
MATERIALS AND METHODS

Patients and Tumors
Tumor tissue was collected from 25 patients (13 males, 12 females) without a history of NF2, who underwent first-time suboccipital resection of a unilateral VS at the Department of Neurosurgery, Haukeland University Hospital, from January 2001 to February 2006. Three patients had been previously treated with Gamma Knife surgery (GKS) for the same VS. Dexamethasone 4 mg 3 4 orally was routinely given, starting the day before surgery. All patients signed an informed consent form releasing tumor tissue for research purposes. Tumor samples were harvested from the subcapsular part and immediately snap frozen and stored in liquid nitrogen in the Bergen Neurosurgical Tissue Bank at Haukeland University Hospital. All samples underwent routine histology and for study purposes a neuropathologist re-examined histology slides and confirmed the diagnosis in all cases. Because VSs originate from Schwann cells that insulate the axons of peripheral nerves and in line with previous studies on VSs, the gene expression profile was compared with that of the peripheral nerve. 10 For this purpose, a 10-mm sample of tibial nerve was harvested from the viable amputation border in 3 patients undergoing leg amputation surgery because of peripheral vascular disease.
and NanoDrop (Thermo Fisher Scientific, New York, New York), respectively. Gene expression microarray analysis was performed on the ABI 1700 Expression Array System (Applied Biosystems, Foster City, California) using the Applied Biosystems Chemo luminescent RT-IVT Labeling Kit and Human Genome Microarray Version 2.0 (Applied Biosystems).
Microarray Data Analysis
Signal intensities were imported into J-Express Pro 2.7 software (MolMine, Bergen, Norway), 12 where interarray quantile normalization was performed to minimize the effect of external variables on the data. We filtered out unreliable spots (signal-to-noise ratio ,3), control spots, and flagged spots. This left us with 23 055 gene probes. The array signals were then log 2 transformed to adjust for outliers in the data set, and we performed an unsupervised hierarchical cluster analysis to define the group to which the samples belonged. All further analyses were done on this filtered data set.
Genes expressed differentially in tumors and controls and within subgroups were identified by significance analysis of microarrays (SAM) 13 with 400 permutations. To limit false positives, we required differentially expressed genes to have a Q value less than 1%, ie, genes on the SAM generated lists had less than 1% chance of being false positive.
To facilitate data interpretation, we included only the top 500 genes after SAM in further analyses and also excluded hypothetical genes with no annotation. Tumor diameter measured at the cerebellopontine angle. c Volume calculated by the XYZ/2 approximation for a tumor sphere. The largest diameter in each plane was defined by analysis of preoperative magnetic resonance imaging.
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cystic versus noncystic VSs; (2) young patients with large tumors versus older patients with small tumors; (3) GKS-treated VSs non-GKS-treated VSs Young patients were defined as younger than 40 years; older patients were older than 50 years. Small tumors were defined having a diameter less than 20 mm; large tumors had to be larger than 25 mm.
Finally, we compared the gene expression profiles of the tumors in our experiment with VS candidate genes indexed in PubMed. The following search terms alone or combined were used: vestibular schwannoma, gene expression, microarray, candidate genes, differentially expressed genes. From these studies, we selected genes reported to be up-or down-regulated and compared them with their expression profiles in our study.
Quantitative Reverse Transcriptase Polymerase Chain Reaction
Selected candidate genes revealed in the microarray experiment were re-examined by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). The detailed procedure of qRT-PCR was reported previously.
11 Gene-specific primers and MGB probes were from Applied Biosystems AssayOnDemand. Quantification of specific mRNA was performed using the ABI 7900 instrument (Applied Biosystems). b--Actin probes were used for endogenous normalization control to adjust for unequal amounts of RNA. Statistical comparisons were performed using the Mann-Whitney test with the GraphPad Prism v.4.0 software (GraphPad Software, Inc, La Jolla, California). P-values were 2 sided and considered significant when ,.05.
Tissue Microarray and Immunostaining
Hematoxylin and eosin-stained routine pathology sections from the 25 sporadic VSs were reexamined, and representative tumor areas encircled. Corresponding areas were then marked on the original (donor) paraffin tissue block. Tissue cylinders (1.0-mm diameter) from these preselected areas were punched out from the donor blocks with a device (Tissue Micro-Array; Beecher Instruments, Sun Prairie, Wisconsin) and then arrayed into a recipient paraffin block. (For review, see Wang et al. 14 ) Three tissue cores were generated from each sample, placed in a defined array on a slide, and cut to a thickness of 7 mm. Based on the results from microarray and qRT-PCR, the tissue array slide was stained with the anti-Caveolin-1 antibody (ab32577, rabbit monoclonal, dilution 1:250; Abcam Ltd, Cambridge, United Kingdom) according to protocol. Omitting the primary antibody served as negative control. As recommended by the antibody manufacturer, we used blood vessel endothelium, adipose tissue, and normal lung tissue (ab4349, lung (human) normal tissue slides; Abcam Ltd) as a positive control. A postmortem tibial nerve was sectioned to 5 mm thickness and immunostained as described. Two pathologists blinded to the gene expression results evaluated the Tissue Micro-Array independently. 
Mutational Screening of NF2 mRNA
The NF2 gene contains 17 exons. 4, 15 With specific primers, we sequenced all exons of the NF2 mRNA. The NF2 gene was PCR amplified from reverse-transcribed RNA using the following primer pairs: NF2 cDNA 1 (5# CCTGTGCAGCAACTCCAG 3#, 3# TGGAAG-CAATTCCTCTTGG 5#), NF2 cDNA 2 (5# ATGAAAAGATCTA-CTGCCCTCC 3#, 3# AAAGAATCGGCTTTCCTTCTC 5#), NF2 cDNA 3 (5# CTGGATAAGAAAATTGATGTCTTC 3 #, 3# CTCCAGGAGCTTCTGCTTG 5#), NF2 cDNA 4 (5# GAGCA-GAAGGTGCTGGAAG 3 #, 3# TCTCTTGATATCTGGTCCATCC 5#). The PCR products were sequenced with the ABI BigDye terminator kit (version 1.1) and the ABI 3730 DNA analyzer. Mutation analysis was performed using the SeqScape software (ABI). 3 ) and the median age was 60 years (range, 59-62 years).
Gene Expression Signatures
Unsupervised hierarchical cluster analysis showed that the VSs were grouped into 2 main clusters consisting of 13 and 9 tumors (Figure 2 ). The following clinical parameters were distributed similarly (ie, no statistically significant difference) in the 2 clusters: sex, age, tumor size, presence of NF2 mutations, tumor subtype (cystic or solid), or previous GKS. A SAM comparing the 2 main clusters showed 1486 differentially expressed genes (Q ,1.0), in which 971 (65.3%) had no currently known biological function. The supervised cluster analysis with SAM comparing VSs and controls revealed 1650 differentially expressed genes, in which the top 500 were further studied. No annotation was found for 51 of the genes, thus leaving 449 for analysis. There were 375 (83.5%) up-regulated and 74 (16.5%) down-regulated genes in the VSs (Tables 2 and 3 for the top 50 genes in each category, respectively). Several cancer-related genes like CAV1, TGFB3, VCAM1, EDNRA, GLI1, GLI2, PRKAR2B, and FZD1 (Table 4) were differentially expressed. With Ingenuity Pathway Analysis, we generated lists of biological functions of which the 449 genes were a part. The top biological functions were cancer, cellular movement, and tumor morphology, to which 133, 77, and 22 genes, respectively, were related (Table 5) . A network linking the top 449 genes was generated, and this showed evidence of involvement of the ERK, Ras, Raf, and Rac pathways (Figure 3) .
The clinical subgroup comparisons with SAM showed that no genes were differentially expressed between cystic and noncystic VSs. For GKS-treated VSs compared with all other VSs, and young patients with large VSs compared with older patients with small VSs, we identified some genes with Q ,1.0. In the GKS groups, the CHMP4C and CXCR7 were down-regulated. Separating young patients with large tumors from the older patients with small tumors, CENTB5, hCG2032698, and ZNF295 were homogeneously down-regulated in the latter group.
From the PubMed search of previously reported VS candidate genes, we found 13 genes that were compared with the respective expression profiles in our study ( Table 6 ). Three of these genes (FGF1, SPARC, PLAT) were differentially expressed in the VSs in our study. Moreover, corresponding to the previous reports, all these genes were up-regulated in our samples.
qRT-PCR
From the list of differentially expressed genes, we selected CAV1, TGFB3, FZD1, MMP17, TGFA, SPARC, and PLAT for verification by qRT-PCR. All these gene probes confirmed the microarray results (Figure 4) . We also found a significant correlation (P = .0006, r 2 = 0.4; Pearson correlation) between the CAV1 expression as measured by microarray and qRT-PCR ( Figure 5 ). Renal a Q, Q value is based on the false discovery rate derived from significance analysis of microarrays; TGF-b, transforming growth factor-b.
Immunohistochemistry
Both pathologists independently found uniform immunonegativity for the anti-Caveolin-1 antibody in all 25 VSs (Figure 6 ), and the human lung and adipose tissue serving as positive control were immunopositive. The Schwann cells of the tibial nerve were strongly immunopositive for CAV1.
Mutational Screening and Expression of NF2
Nineteen of 25 VSs had NF2 mutations, with deletions being most frequent and found in 18 of the samples (Table 7 ). All control nerves had an intact NF2 gene. The proportion of NF2 mutations in the 2 main clusters of VSs was comparable (P = 1.0). The average expression signals of the 3 NF2 transcripts (ABI 1700 probe ID 180208, 143151, 185345) in the VSs were 5743, 3458, 1353; in the control nerves, there were 7042, 4778, 1756, respectively. There was no significant difference (P . .13) in the average signals among these groups; hence, there was no significant difference in mRNA expression levels in VSs with a mutated or intact NF2 gene (Figure 7 ).
DISCUSSION
We examined the total gene expression profile of 25 sporadic VSs and compared them with samples from 3 normal peripheral nerves. The main finding was the uniform down-regulation of the tumor suppressor gene CAV1 shown by mRNA microarray, qRT-PCR, and immunohistochemistry. Based on the average microarray signal, the gene was 12.9-fold down-regulated in the VSs The CAV1 protein was not detected in any of the 25 VSs, as opposed to the strong immunopositivity in normal Schwann cells of the tibial nerve. There was very little variation in expression within the group of tumors, seen both at the mRNA and protein levels. It is shown in other tumors that the CAV1 protein is located in the cell membrane and has been linked to cancer-associated processes like transformation, tumor growth, cell migration and metastasis, and cell death. [16] [17] [18] [19] [20] [21] [22] It has been reported to function as a tumor suppressor. [23] [24] [25] [26] [27] Being a member of the integrin-signaling pathway, down-regulation of CAV1 has been implicated in osteosarcomas and Ewing's sarcoma cells, and a tumor suppressor effect has been found in breast cancer cells and squamous cell carcinoma. 24, 25, [27] [28] [29] Importantly, CAV1 is expressed in both normal Schwann cells as well as in Schwann cell-derived cell lines from rats. 30 Hence, based on its uniform down-regulation in VSs, its putative role in tumorigenesis, and its normal expression in Schwann cells, we hypothesize that CAV1 acts as tumor suppressor in VSs. Because VSs are benign and CAV1 has an established role in neoplasia, we suggest that deregulation of this gene is an early event in tumorigenesis.
The principal finding from the unsupervised cluster analysis of 23 055 gene probes was the presence of 2 distinct clusters, in which 13 and 9 of the 25 VSs were located. We were unable to detect any common clinical factor associated with this clustering. The result suggests the existence of 2 main subtypes of VSs in which the general gene expression profiles differ and the difference between the two is not detected by standard histology. Such differences may theoretically explain tumor variations in response to irradiation or drugs as well contribute to phenotypical variation (ie, proliferation rate, growth rate).
The supervised cluster analysis with SAM revealed several genes deregulated in VSs, many of which differed 100-fold between tumors and controls. Importantly, we found that the majority of genes were related to cancer (133 genes, Table 5 ). A network integrating the current knowledge on the differentially expressed genes showed involvement of the Ras, Raf, and Rac pathways and that the ERK pathway was the core linking these genes (Figure 3) . Supporting the importance of this pathway in VSs, an in vitro study on human schwannomas found that the basal activity of the ERK pathway was increased in schwannoma cells compared with normal Schwann cells. 31 Many of the cancerassociated genes that were present in our list of differentially expressed genes have a hitherto unrecognized role in VS pathophysiology (Table 4) . Among them, we found the growth factorrelated TGFB3 that has been associated with breast cancer. Moreover, 3 members (GLI1, GLI2, PRKAR2B) of the sonic hedgehog-signaling pathway were down-regulated in the VSs. This pathway is activated in various malignant cancer types and is important in the morphogenesis and left-right orientation in the developing embryo. Visual system development and function 14 .0001-.02
a P values were calculated by the Ingenuity Pathways Analysis package (Ingenuity Systems), using the Fisher exact test (right sided) as described in Materials and Methods.
As previously mentioned, only a few global gene expression studies on sporadic VSs have been performed. These studies have included a small number of cases that were mixtures of sporadic and NF2-related VSs as well as peripheral schwannomas. To evaluate the transcription levels of the genes reported in these studies, we compared them with the expression levels in our data set. We found similar expression trends (eg, up-or down-regu lated) for 8 of the 13 reported candidate genes, but only 3 (SPARC, PLAT, FGF1) of them were differentially expressed in our microarray study. This is important in 2 ways: (1) it adds validity to our microarray study in general and (2) it adds more evidence of a role of these genes in VS biology.
Regarding the NF2 gene, all 3 transcripts had similar expression signatures. Some VS samples had higher signals than the controls; however, there was no significant difference in the array signals between the VSs and normal nerves. The 2 main VS clusters had similar proportions of NF2 gene mutations. Thus, the clustering was unlikely to be caused by NF2 gene mutations. With sequencing of the NF2 mRNA, we found nonmutated mRNA in 6 of 25 VSs. The most frequent mutations were found in exons 2, 3, and 15. We found that VSs with an intact NF2 gene had no significant difference in NF2 mRNA expression level compared with the VSs with a mutated NF2 gene for all 3 isoforms of the gene. The highest NF2 mRNA levels were found in the samples with a mutated NF2 gene. This indicates that the present mutations did not alter the transcription of the gene. To our knowledge this has not been reported previously. On this basis, we suggest that other gene regulatory mechanisms like FIGURE 3 . A network that associated the differentially expressed genes between 25 vestibular schwannomas and controls with current knowledge in the Ingenuity database (www.ingenuity.com) showed that the ERK pathway is the core linking these genes. The Ingenuity Pathway Analysis software was used to generate this network. Circles, boxes, or triangles represent genes. Lines connecting symbols represent known interactions in the Ingenuity database (solid lines are direct interaction, dashed lines are indirect interaction). Colored symbols represent genes present in the list of differentially expressed genes (red is up-regulated, green is down-regulated). The numbers below the symbols shows the fold change between vestibular schwannomas and controls. A legend explaining the shape of the symbols is shown to the right.
epigenetic regulation contribute to the expression levels of NF2 mRNA. Altogether, our results support that the NF2 gene is not universally mutated in sporadic VSs.
The subgroup comparisons showed a few differentially expressed genes for (1) GKS-treated VSs compared with all other VSs and (2) young patients with large VSs compared with older patients with smaller VSs. The following genes in each group had Q ,1.0: CHMP4C and CXCR7 were down-regulated in the GKS group, and CENTB5, hCG2032698, and ZNF295 were up-regulated in the younger patients with large VSs. CHMP4C belongs to the chromatin-modifying protein/charged multivesicular body protein (CHMP) family. The orphan receptor CXCR7 has been suggested as a link between inflammation and cancer. The functional properties of CENTB5, hCG2032698, and ZNF295 have not been thoroughly investigated. The small number of differentially expressed genes reflected the unsupervised cluster analysis in which there was a random distribution of the clinical subgroups in the 2 clusters. However, in addition to the arbitrary and somewhat crude categorizations of age and VS size, it is possible that we included too few samples of each category to successfully find more differentially expressed genes.
Because all the VS patients were treated with oral dexamethasone from the day before surgery, it is possible that this could cause altered expression of steroid-sensitive genes. Therefore, we analyzed the expression of the strongest cancer-related candidate genes (Table 4) , including CAV1, in a microarray experiment of a panel of human lymphocytes before and after administration of dexamethasone (data not shown). For all the genes reported here, there a Genes with more than 1 ABI probe ID indicates different transcripts of the particular gene. Q, Q value is based on the false discovery rate derived from significance analysis of microarrays.
was no change in expression before and after dexamethasone treatment, thus supporting the validity of these putative VS genes. Limitations of our study are the number and source of control tissue. The source of controls was tibial nerves harvested during leg amputation surgery. Surrounding the peripheral nerves, the main cell types are Schwann cells and fibroblasts, with the former being abundant. 32 In some studies of VSs, VNs have been used as a source of Schwann cells, 9 whereas others have used peripheral nerves. 7 In the VNs, the border between central (oligodendroglia) and peripheral (Schwann cells) myelinization is found at the porus acusticus internus. 33 Therefore, if sampling of a VN occurs proximal to the porus acusticus internus, one will have oligodendroglia, not Schwann cells as controls. This issue has not been addressed in the previous studies using the VN as control tissue.
Although VSs are homogeneous histologically, the total transcriptional profile of 23 055 genes divided the 25 VS into 2 subgroups. Among the differentially expressed genes between the whole group of VS and control nerves, cancer-associated genes were abundant. An integrating network of the differentially expressed genes showed that the ERK pathway was the core linking these genes. Several novel candidate genes were identified. Based on the uniform down-regulation at both the mRNA and protein levels of the integrin signaling pathway gene CAV1, we hypothesize that loss of this tumor suppressor gene contributes to the formation of VSs. Finally, the previously reported VS 
